Why the study?
Are direct oral anticoagulants safe and effective for treating deep vein thrombosis and venous thromboembolism in pediatric patients?
Are direct oral anticoagulants safe and effective for treating deep vein thrombosis and venous thromboembolism in pediatric patients?
While DOACs offer a potential alternative to warfarin without frequent monitoring, there is currently insufficient evidence to recommend their routine use in pediatric patients.
Answers are grounded in this paper and cite their sources.
Insufficient evidence precludes routine pediatric DOAC use for VTE; leaves open need for dedicated trials.
Common treatment options for deep vein thrombosis and venous thromboembolism in the pediatric population include unfractionated heparin, low molecular weight heparin, and warfarin. Other alternatives are bivalirudin, argatroban, and fondaparinux. Warfarin is the only approved oral option, but an oral agent without frequent monitoring would be optimal for pediatric patients. Thus, there is an increasing need for new anticoagulation options in this population. None of the current direct oral anticoagulants have FDA-approved indications and dosing in children. The two classes of DOACs and the drugs they are comprised of are factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and direct thrombin inhibitor (dabigatran). Off-label usage of these agents is largely based on adult doses. By far, rivaroxaban and dabigatran have the most published data and ongoing trials in pediatric patients compared to edoxaban and apixaban. After evaluating the current literature available on these agents, it is, however, still too early to make any definitive recommendations on their usage in this special population.
No takes yet. Share an insight, caveat, or question.
Vajna et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: